First cell-active covalent EGFR inhibitor described
Aug. 31, 2023
Epidermal growth factor receptor (EGFR) is involved in cell proliferation leading to malignant transformation, and for that it is considered a therapeutic target for treatment and prevention in lung and other cancers.